Aclaris Therapeutics, Inc. (ACRS) Is Set To Soar And Too Cheap To Ignore
For most investors, the 1.72% change in Aclaris Therapeutics, Inc., (ACRS) could have prompted them to buy the stock, but doing that would be a mistake as it would be taking into consideration only the short-term performance of the stock. The stock closed August 15, 2019 trading at $0.8 which saw uptrend of -89.18% since the beginning of 2019. The price of the stock has risen by 1012.5% from average 12-month price target of $8.9 expected by the analysts. Most analysts believed that the stock has the potential to rise by 2650% or more. For Aclaris Therapeutics, Inc. to record further gain analysts believe that the company has to hit $22 price target. The high price target for ACRS for next 12 months currently stands at $22. This means that the highest 12 months price target is 2650% above ...